Telix Pharmaceuticals prices and upsizes US$600 million convertible bond offering with Singapore listing, backed by J.P. Morgan delta placement
Telix Pharmaceuticals (ASX/NASDAQ: TLX), the Australian oncology radiopharmaceutical company, has successfully priced and upsized its convertible notes offering from an initial US$550 million to US$600 million due to strong investor demand. The notes, which carry a coupon of 1.50 per cent and are due in 2031, are issued by Telix's wholly-owned subsidiary Telix Pharmaceuticals (Investments) Inc., with guarantees provided by Telix and Telix Pharmaceuticals (US) Inc. The convertible bonds (instruments that pay a fixed coupon but can be converted into equity at a preset price) are intended to be listed on the Official List of Singapore Exchange Securities Trading Limited (SGX-ST), rather than on a US or Australian exchange. Telix will use the proceeds to concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029 — making this a refinancing of the prior facility rather than a primary capital raise. J.P. Morgan executed a concurrent delta placement — a sale of ordinary shares designed to allow convertible bond investors to hedge their equity exposure — at a clearing price of A$14.22 per share, representing an 8.0 per cent discount to Telix's closing price of A$15.45 on 14 April 2026. The reference share price determined through the delta placement sets the initial conversion price for the bonds. The deal was priced on 14 April 2026, with final terms confirmed prior to market open on 15 April.
Why this matters
The upsizing from US$550 million to US$600 million signals robust institutional appetite for convertible debt from high-growth life sciences issuers — a market segment that has reopened in 2026 after a period of rate-driven suppression. The Singapore listing choice is notable: issuers increasingly use the SGX-ST for convertible bonds targeting Asian institutional investors while maintaining primary equity listings in Australia and the US, raising questions of multi-jurisdictional disclosure compliance and listing rules alignment. The delta placement mechanism is a standard market practice that requires careful coordination between equity capital markets counsel, the issuer's securities lawyers, and the placement agent to ensure simultaneous execution without triggering market abuse concerns under applicable rules. For law firms, convertible bond mandates of this size involve prospectus or offering memorandum drafting, verification, comfort letter coordination, and the listing application process for SGX-ST.
On the Ground
On this deal, a trainee would assist with verification notes — the process of checking every factual statement in the offering memorandum against source documents — and coordinate comfort letters from auditors confirming the accuracy of financial information. They would also assist with the SGX-ST listing application forms and manage the timeline for the delta placement share issuance documentation.
Interview prep
Soundbite
Convertible bond upsizings signal life sciences capital markets are reopening — and Singapore's listing flexibility is drawing cross-listed issuers.
Question you might get
“Why would an issuer choose to list convertible bonds on the SGX-ST rather than a US exchange, and what legal considerations does that choice create for English or Australian-law-governed issuers?”
Full answer
Telix Pharmaceuticals has priced a US$600 million convertible note offering due 2031, upsized from US$550 million on strong demand, with the bonds to be listed on the SGX-ST. The concurrent delta placement by J.P. Morgan — selling ordinary shares at a discount to set the conversion price — is a textbook convertible bond structuring technique that requires tight cross-border execution. For law firms, this activates equity capital markets, Singapore listing rules expertise, and US securities law compliance simultaneously. It reflects the broader reopening of convertible debt markets for investment-grade-quality growth companies after two years of rate headwinds. The life sciences sector, where revenue visibility from radiopharmaceutical pipelines supports debt servicing, is likely to see further convertible issuance through H2 2026.
Sources
My notes
saved